This brand name is authorized in Albania, Estonia, Lithuania
The drug BERLIPRIL contains one active pharmaceutical ingredient (API):
|
1
Enalapril
UNII 9O25354EPJ - ENALAPRIL MALEATE
|
|
Enalapril is hydrolysed via hepatic CES 1 to the active metabolite enalaprilat, which acts as an ACE inhibitor. ACE is a peptidyl dipeptidase which catalyses the conversion of angiotensin I to the vasoconstrictor substance angiotensin II and hence inhibition of ACE results in decreased plasma angiotensin II. This also leads to increased plasma renin activity and decreased aldosterone secretion. The mechanism of action of enalapril is therefore primarily via the suppression of the RAAS. However, ACE is identical to kininase II, and so enalapril may also exert its effects by blocking the degradation of bradykinin, a potent vasodepressor peptide. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C09AA02 | Enalapril | C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09A ACE inhibitors, plain → C09AA ACE inhibitors, plain |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: AL | Fondi i Sigurimit të Detyrueshëm të Kujdesit Shëndetësor | Identifier(s): 87/16 |
| Country: EE | Ravimiamet | Identifier(s): 1013599, 1013601, 1017470, 1074080, 1074091, 1087297, 1087309, 1087310, 1087321, 1114401 |
| Country: LT | Valstybinė vaistų kontrolės tarnyba | Identifier(s): 1000324, 1003476, 1003477, 1011918, 1011919, 1011920, 1011921, 1014066, 1014067, 1014068 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
